SCHEMBL5824985

SCHEMBL5824985

COc1cc2nccc(Oc3ccc(NC(=S)NCCCN4CCN(C)CC4)c(C)c3C)c2cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 3/20 0.49
MET P08581 10/20 0.49
EGFR P00533 3/20 0.49
PDGFRB P09619 1/20 0.49
KIT P10721 1/20 0.49
KDR P35968 1/20 0.49
FLT3 P36888 1/20 0.49
AXL P30530 7/20 0.49
PLK4 O00444 2/20 0.49
AURKA O14965 2/20 0.49
GAK O14976 2/20 0.49
RIPK2 O43353 2/20 0.49
PRKAB2 O43741 2/20 0.49
ERN1 O75460 2/20 0.49
STK10 O94804 2/20 0.49
FYN P06241 2/20 0.49
YES1 P07947 2/20 0.49
LYN P07948 2/20 0.49
SRC P12931 2/20 0.49
FER P16591 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5825797 0.93 MET (0.51) QPCTMETFGFR2
SCHEMBL5825310 0.92 AXL (0.54) QPCTMETEGFRPDGFRBKIT
SCHEMBL5825541 0.89 MET (0.49) QPCTMETEGFRPDGFRBKIT
SCHEMBL5825883 0.88 ACHE (0.52) METKITAXLFGFR2
SCHEMBL5824755 0.84 AXL (0.49) QPCTMETPDGFRBKITFLT3
SCHEMBL5825031 0.82 FGFR2 (0.49) METPDGFRBKITKDRAXL
SCHEMBL5825673 0.82 FGFR2 (0.52) METPDGFRBKITKDRAXL
SCHEMBL5825604 0.82 FGFR2 (0.49) METPDGFRBKITKDRAXL
SCHEMBL5824408 0.81 AXL (0.52) QPCTMETEGFRPDGFRBKIT
SCHEMBL5825703 0.80 FGFR2 (0.51) METPDGFRBKITKDRAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135466-B2 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-11-14 US claimed
US-7135466-B2 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-11-14 US disclosed
US-20060211717-A1 Quinoline and quinazoline derivatives and drugs containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-21 US disclosed
US-20040132727-A1 Quinoline and quinazoline derivatives and drugs containing the same KIRIN HOLDINGS KABUSHIKI KAISHA (JP) 2004-07-08 US disclosed
EP-1243582-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2002-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211717-A1 Quinoline and quinazoline derivatives and drugs containing the same PDGFRA, PDGFRB, PDGFA QPCT 994/4885MET 84/4885EGFR 24/4885
US-20040132727-A1 Quinoline and quinazoline derivatives and drugs containing the same PDGFRA, PDGFRB, PDGFA QPCT 906/4885MET 40/4885EGFR 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.